Tony Mok, MD, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with non-small cell lung cancer after the phase III KEYNOTE-042 trial.
Tony Mok, MD, a professor in the department of clinical oncology at the Chinese University of Hong Kong, discusses the next steps for pembrolizumab (Keytruda) as a treatment option for patients with nonsmall cell lung cancer (NSCLC) after the phase III KEYNOTE-042 trial.
The current standard indication has been well-defined by a number of available studies as either monotherapy or in combination, says Mok. One of the next steps includes answering the question of how resistance to single-agent pembrolizumab can be managed.
The next step includes identifying how pembrolizumab can be used as a frame for other immunotherapy agents. Mok says it is still very risky business as there are several negative data that have come out already, but if there is an advantage, it needs to be used.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More